The Law Offices of Frank R. Cruz announces an investigation of Neovasc, Inc (Neovasc or the Company) (NASDAQ: NVCN) on behalf of investors concerning the Companys possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
Neovascs Reducer is a medical device that treats refractory angina by altering blood flow in the hearts circulatory system. In December 2018, the Company filed a Q-Sub submission to the U.S. Food and Drug Administration (FDA) that contained safety and efficacy results from Neovascs clinical studies, as well as supporting data from peer-reviewed journals.
On February 20, 2019, the Company announced that, despite Breakthrough Device Designation, the FDA review team recommended collection of further pre-market blinded data prior to Pre-Market Approval (PMA) submission.
On November 1, 2019, Neovasc announced that it would submit a PMA application for the Reducer without gathering further evidence, against the FDAs recommendation. The Company claimed that the clinical evidence already available will be sufficient to not further delay the availability of this Breakthrough medical device for the treatment of U.S. patients.
On October 28, 2020, before the market opened, Neovasc announced that an FDA advisory committee voted overwhelmingly against issuing a reasonable assurance of effectiveness and on whether the relative benefits outweighed the relative risks. The panel echoed concerns previously raised by the FDA about the lack of sufficient data.
On this news, the Companys share price fell $0.77, or 42%, to close at $1.06 per share on October 28, 2020, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased Neovasc securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to email@example.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.